CLDX (Celldex Therapeutics) Forward P/E Multiple
The 12-month forward P/E for Celldex Therapeutics (CLDX) is recorded at 0.00 on this GURU.Markets platform chart. The asset's price action remains independent of macroeconomic trends, reacting solely to scientific reports and the risk of secondary offerings. Investor confidence rests on the authority of Celldex Therapeutics (CLDX) in developing targeted antibodies, while the strategy focuses on expanding clinical trials to attract global partners.
Analytical breakdowns for Celldex Therapeutics
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
Total Debt to Equity Ratio Celldex Therapeutics|CLDX - Long-Term Debt to Capital|Short-Term Debt to Equity Celldex Therapeutics|CLDX - Company Aggregate Debt|Debts to Book Capitalization Celldex Therapeutics Inc|CLDX - Long-Term Debt|Company Short-Term Debts Celldex Therapeutics|Quick Ratio celldex.com
- company profitability and valuation multiples indicators:
CLDX - Company Net Income|Expected Profit Celldex Therapeutics|CLDX - Price to Earnings Ratio|Future Price to Earnings Celldex|CLDX - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Celldex Therapeutics Inc|CLDX - Operating profit before amortization|Net earnings per share (EPS TTM) Celldex Therapeutics|CLDX - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months celldex.com|CLDX - Earnings per share growth this year|Expected earnings per share growth for next year Celldex Therapeutics
Summary company analytics:Celldex Therapeutics, Inc.
Investors often face a choice between current undervaluation and future growth potential. By analyzing the forward P/E chart for Celldex Therapeutics (CLDX), one can assess the relationship between market value and projected earnings. This ratio reflects market expectations regarding the pace of asset monetization. For Celldex Therapeutics (CLDX), this metric correlates directly with successes in the development of targeted antibodies. A high multiple here confirms the market's belief in the technological superiority of the R&D sector.
Competitors of Celldex Therapeutics (CLDX)
Projected Price to Earnings ARGX (argenx)|BNTX (BioNTech Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (abivax.com)|Market Cap to Projected Earnings ADMA Corp (ADMA)|PTGX - Future Price to Earnings|immunovant.com (IMVT) - Projected Price to Earnings|Kiniksa (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols SA|Projected Price to Earnings ADPT|Forward P/E Multiple Aurinia Corp|Future Price to Earnings BioCryst (BCRX)|veratx.com - Price to Future Earnings Ratio|Forward P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Projected Price to Earnings Ratio|AbCellera Bio - Forward P/E Multiple|Tourmaline (TRML) - Projected Price to Earnings|PGEN: Forward P/E Multiple|Projected Price to Earnings Ratio pharming.com (PHAR)|Future Price to Earnings Nektar Therapeutics Inc.|Future Price to Earnings UPB|Future Price to Earnings Zenas Biopharma, Inc. (ZBIO)|Future Price to Earnings IMNM (Immunome Bio)|Forward P/E Multiple GOSS (Gossamer Bio, Inc.)|KALV: Price to Future Earnings Ratio|Septerna - Forward P/E Multiple|Projected Price to Earnings Ratio Pieris Pharma|SVRA (Savara Corp) - Projected Price to Earnings|Price to Future Earnings Ratio RIGL|Projected Price to Earnings ANAB|ATXS: Future Price to Earnings Multiple|Projected Price to Earnings ENGN (enGene)|Market Cap to Future Earnings Ratio RAPT|Forward P/E Multiple JBIO (Aerovate Therapeutics)|Future Price to Earnings Multiple ACRS|Kyverna Therapeutics - Forward P/E Multiple|Projected Price to Earnings Ratio tizianalifesciences.com|Cabaletta Bio (CABA) - Future Price to Earnings|Ventyx Biosciences Inc. - Future Price to Earnings Multiple|THTX (Theratechnologies Inc) - Forward P/E Multiple|Forward P/E Multiple Avalo Therapeutics Inc|Future Price to Earnings Eledon Pharmaceuticals (ELDN)|AGEN: Price to Expected Earnings Ratio|Forward P/E Multiple CLYM (Climb Bio)|Zura Bio Ltd (ZURA) - Projected Price to Earnings Ratio|ATYR: Projected Price to Earnings|ADAG - Forward P/E Multiple|IMA (ikenaoncology.com) - Projected Price to Earnings|STTK: Market Cap to Future Earnings Ratio|EQ (Equillium Inc) - Forward P/E Multiple|Connect Pharma (CNTB) - Market Cap to Projected Earnings|Forward P/E Multiple IMUX|Projected Price to Earnings atarabio.com ATRA|Future Price to Earnings InflaRx IFRX|Market Cap to Projected Earnings x4pharma.com (XFOR)|Adicet - Forward P/E Multiple|Celularity Inc. (CELU) - Projected Price to Earnings|INmune Bio Corp (INMB) - Future Price to Earnings|BRNS (Barinthus Biotherapeutics Corp) - Future Price to Earnings|KZR (Kezar Life Sciences) - Forward P/E Multiple|Price to Future Earnings Ratio SABS (sabbiotherapeutics.com)|Projected Price to Earnings AKTX (Akari Therapeutics Plc)|enlivex.com - Price to Future Earnings Ratio|Future Price to Earnings Q32 Bio QTTB|GOVX (GeoVax Corp) - Price to Expected Earnings Ratio|Edesa Biotech, Inc. - Forward P/E Multiple|Future Price to Earnings Multiple IBIO (ibioinc.com)|CARM: Forward P/E Multiple|XTL Biopharmaceuticals Ltd (XTLB) - Forward P/E Multiple|Future Price to Earnings Bolt Biotherapeutics Inc.|HCWB: Future Price to Earnings Multiple|Future Price to Earnings Aptevo Therapeutics (APVO)|Projected Price to Earnings AIM ImmunoTech, Inc. AIM|Forward P/E Multiple ADTX (Aditxt, Inc.)|Forward P/E Multiple GRI Bio Inc GRI|XRTX: Projected Price to Earnings|Future Price to Earnings Multiple HIND (Vyome Therapeutics)|REVB: Forward P/E Multiple|INDP - Market Cap to Projected Earnings|Future Price to Earnings Scinai Immunotherapeutics Ltd.|Projected Price to Earnings CalciMedica Corp (CALI)|Future Price to Earnings Affimed (AFMD)|Projected Price to Earnings allakos.com ALLK|HOOKIPA Pharma - Projected Price to Earnings|Forward P/E Multiple IGM Biosciences Inc. IGMS|ITOS - Future Price to Earnings|OCEA (Ocean Biomedical Inc) - Price to Future Earnings Ratio|TCBP: Forward P/E Multiple|Projected Price to Earnings Ratio Third Harmonic Bio Inc (THRD)
